- ProMIS Neurosciences (PMN) has initiated the commercialization of its COVID-19 serology assay
- Seasoned industry executive and entrepreneur, Owen Dempsey to lead the commercialization program
- Owen’s professional work for the past 25 years has been to build companies founded to discover and commercialize antibodies in applications including life science research, pharmaceutical drug discovery and clinical diagnostics
- This advanced serology test developed by ProMIS Neurosciences measures not only serum antibodies to SARS-CoV-2, but also their protective activity against infection
- The initial marketing and commercialization of the assay will be directed only to vaccine manufacturers, pharmaceutical companies and government organizations
- ProMIS Neurosciences, Inc. is a development-stage biotechnology company
- ProMIS Neurosciences Inc. (PMN) is up 10.81 per cent, trading at C$0.205 per share at 1:30 pm ET
ProMIS Neurosciences (PMN) has initiated the commercialization of its COVID-19 serology assay and appointed Owen Dempsey to lead the commercialization program.
Owen’s professional work for the past 25 years has been to build companies founded to discover and commercialize antibodies in applications including life science research, pharmaceutical drug discovery, clinical diagnostics and therapeutic treatment of cancer, AIDS and other serious illness. He has led private, venture-backed as well as NASDAQ-listed companies and is a past board member of ALDA, the Analytical, Life Science & Diagnostics Association.
“I am delighted to lead this opportunity on behalf of ProMIS Neurosciences,” stated Owen Dempsey. “Our serology assay commercialization efforts will be targeting the need for a highly accurate test to detect, quantify and characterize antibodies against the virus causing COVID-19, either as a consequence of contracting the viral disease or in response to vaccination. Our initial focus will be on commercialization to the medical and public health community, vaccine developers, pharmaceutical companies, governmental agencies and other organizations.”
This advanced serology test developed by ProMIS Neurosciences measures not only serum antibodies to SARS-CoV-2, the novel coronavirus causing COVID-19 but also their protective activity against infection.
The assay simultaneously assesses antibody levels in the blood of study participants and their neutralizing activity against the original strain of SARS-CoV-2 as well as emerging variants.
Variants can be added to the assay as they are identified. The assay utilizes an advanced, high-throughput, sensitive and accurate surface plasmon resonance (SPR) technology as opposed to traditional ELISA (enzyme-linked immunosorbent assay) methods.
In commercializing an advanced serology testing platform, the company aims to meet the needs of the medical community and investigators in academia, industry and government working to assess response and durability of response to vaccines as well as to monitor and assess antibody response to emerging strains of the virus. As reported in the scientific literature, ProMis’s accurate and sensitive format is capable of measuring neutralizing antibodies that inhibit coronavirus RBD binding to the human ACE2 receptor. This and similar collaborative efforts may help to provide guidance regarding the need for boosters or modified vaccines addressing emerging strains.
The initial marketing and commercialization of the assay will be directed only to organizations such as vaccine manufacturers, pharmaceutical companies and government organizations at the national and state/provincial level. The assay is not currently available to the general public.
ProMIS Neurosciences, Inc. is a development-stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD).
ProMIS Neurosciences Inc. (PMN) is up 10.81 per cent, trading at C$0.205 per share at 1:30 pm ET.
